OPKO Health (OPK) FDA Approvals

OPKO Health logo
$1.62 +0.01 (+0.31%)
As of 02:50 PM Eastern
This is a fair market value price provided by Massive. Learn more.

OPKO Health's Drugs in the FDA Approval Process

This section highlights FDA-related milestones and regulatory updates for drugs developed by OPKO Health (OPK). Over the past two years, OPKO Health has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as OPK-8801001, MDX2004, OPK-88006, and MDX2201. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. Select a button below to view the list of FDA events for that drug.

OPK-8801001 FDA Regulatory Events

OPK-8801001 is a drug developed by OPKO Health for the following indication: for Acromegaly. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

MDX2004 FDA Regulatory Events

MDX2004 is a drug developed by OPKO Health for the following indication: Treatment of Advanced Cancers. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

OPK-88006 FDA Regulatory Events

OPK-88006 is a drug developed by OPKO Health for the following indication: for patients with obesity, metabolic and fibrotic disorders. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

MDX2201 FDA Regulatory Events

MDX2201 is a drug developed by OPKO Health for the following indication: Epstein-Barr Virus Vaccine Candidate. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

OPKO Health FDA Events - Frequently Asked Questions

In the past two years, OPKO Health (OPK) has not received FDA approval for any therapies. However, the company does have drugs under review or in active clinical development.

In the past two years, OPKO Health (OPK) has reported FDA regulatory activity for the following drugs: OPK-8801001, MDX2004, OPK-88006 and MDX2201.

The most recent FDA-related event for OPKO Health occurred on October 27, 2026, involving OPK-8801001. The update was categorized as "Dose Update," with the company reporting: "OPKO Biologics Ltd announced that the first participant has been dosed in a first-in-human Phase 1/2a clinical trial of OPK-8801001, an investigational, long acting human growth hormone receptor antagonist being developed for the treatment of acromegaly."

Current therapies from OPKO Health in review with the FDA target conditions such as:

  • for Acromegaly - OPK-8801001
  • Treatment of Advanced Cancers - MDX2004
  • for patients with obesity, metabolic and fibrotic disorders. - OPK-88006
  • Epstein-Barr Virus Vaccine Candidate - MDX2201
  • NDA: New Drug Application
  • ANDA: Abbreviated New Drug Application
  • sNDA: Supplemental New Drug Application
  • BLA: Biologics License Application
  • sBLA: Supplemental Biologics License Application
  • FDA Approved: Approved by the FDA
  • EMA: European Medicines Agency
  • CE Mark: European Union Certification
  • NMPA: China National Medical Products Administration
  • MHLW: Japanese Ministry of Health
  • FDA Meeting: Consultation with FDA
  • Pre-IND: Pre-Investigational New Drug Meeting
  • Breakthrough Therapy: Special FDA designation for promising therapies
  • Fast Track: Accelerated FDA approval pathway
  • Orphan Drug: Designation for rare disease treatments
  • RPD: Rare Pediatric Disease Designation
  • RMAT: Regenerative Medicine Advanced Therapy
  • DSMB Review: Data Safety Monitoring Board Review
  • IDMC Review: Independent Data Monitoring Committee
  • MAA: MHRA Marketing Authorization Application
  • RTF: Refusal to File (Rejected Application)
  • 510(k): FDA Clearance for Medical Devices
  • Rolling Submission: Staggered regulatory review process

FDA progress for NASDAQ:OPK last updated on 10/27/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data.
From Our Partners